NEW YORK, May 22, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. ( PGNX) announced today that results from a trial evaluating the use of its automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC) have been published online in JAMA Oncology.
Progenics Announces JAMA Oncology Publication Highlighting Company’s Imaging Analysis Platform
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться